[3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain

https://doi.org/10.1016/0014-2999(91)90063-VGet rights and content

Abstract

CGP 39653 (D,L-(E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid) was initially discovered to inhibit the binding of [3H]L-glutamate and [3H]3-((±)2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid ([3h]CPP) with Ki values of 230 and 5 nM, respectively. The radiolabeled compound [3H]CGP 39653 binds to rat frontal cortical membranes in a saturable and reversible manner. Analysis of saturation experiments revealed that the ligand labels one binding site with a Kd value of 6nM. Competition experiments indicated that the order of potency of a number of competitive excitatory amino acid agonist and antagonist compounds was similar to that found previously for other N-methyl-D-aspartate (NMDA) receptor ligands. In contrast to these competitive inhibitors, which produced steep inhibition curves, glycine inhibited binding in a complex manner. When the functional activity of the unlabeled compound was explored, CGP 39653 blocked NMDA-evoked dopolarizations in the rat cortical wedge in vitro and inhibited L-glutamate stimulated [3H]N(1-[2-thienyl]cyclohexyl)3,4-piperidine ([3H]TCP) binding in cortical membranes. These results suggest that [3H]CGP 39653 selectively binds to the NMDA receptor as an antagonist with high affinity and is currently the ligand of choice for labeling the NMDA receptor.

References (20)

There are more references available in the full text version of this article.

Cited by (216)

  • Pharmacological characterization and binding modes of novel racemic and optically active phenylalanine-based antagonists of AMPA receptors

    2017, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Rat brain membrane preparations used in native receptor binding experiments were prepared according to the method described by Ransom and Stec [37]. Affinity for AMPA [38] KA [39] and NMDA [40] receptor sites was determined using 5 nM [3H]AMPA, 5 nM [3H]KA, and 2 nM [3H]CGP 39653 (all from Perkin Elmer, Waltham, MA) with some modifications as previously described [41]. Recombinant rat AMPA receptor binding.

  • New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]pyrrolidine-2,5-diones

    2016, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    Antinociceptive activity in the formalin hind paw test was examined according to the method described previously.47,48 Sodium, calcium channels (L-type), and NMDA receptors binding studies were performed commercially in Cerep Laboratories (Poitiers, France) using testing procedures described elsewhere (Na+ channel—site 2,33 L-type Ca2+ channel,49 NMDA receptors50). All experiments were performed in duplicate.

View all citing articles on Scopus
1

Ciba-Geigy Pharmaceutical Research Division, CH-4002 Basel, Switzerland.

2

NEN-Dupont, 549 Albany Street, Boston, MA, U.S.A.

3

Current address: Abbott Laboratories, D-47W, Abbott Park, IL, U.S.A.

View full text